iA Global Asset Management Inc. Trims Stake in Alnylam Pharmaceuticals, Inc. $ALNY

iA Global Asset Management Inc. lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,922 shares of the biopharmaceutical company’s stock after selling 1,858 shares during the quarter. iA Global Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,268,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. MV Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $25,000. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. Finally, Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $32,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright still reiterated a Buy rating and a $470 price target, signaling the firm remains bullish on Alnylam Pharmaceuticals’ long-term outlook despite trimming near-term estimates.
• Positive Sentiment: HC Wainwright raised its FY2030 earnings estimate to $19.93 per share from $19.65, suggesting confidence in the company’s longer-term growth potential.
• Neutral Sentiment: Barclays also recently initiated or reiterated a Buy stance on Alnylam, adding another supportive analyst view for the stock. Article Title
• Negative Sentiment: HC Wainwright lowered its FY2026 earnings estimate to $6.51 per share from $7.86, implying softer expectations for the current year and potentially pressuring the stock.
• Negative Sentiment: The firm also cut its Q2 2026, Q3 2026, Q4 2026, FY2027, FY2028, and FY2029 EPS forecasts, which may reinforce concerns that near-term profit growth could be slower than previously expected.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $301.67 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $273.11 and a 12-month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The business’s fifty day simple moving average is $295.37 and its 200-day simple moving average is $329.02. The company has a market capitalization of $40.28 billion, a price-to-earnings ratio of 82.42 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the company posted ($0.44) earnings per share. The firm’s quarterly revenue was up 96.4% on a year-over-year basis. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ALNY. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Royal Bank Of Canada reduced their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Chardan Capital reiterated a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $461.39.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.